Change Healthcare Inc. Reports Fourth Quarter and Full Year Fiscal 2022 Financial Results

May 25, 2022 at 4:15 PM EDT
  • Strong revenue and cash flow growth driven by continued momentum in core business and investment in expanded capabilities
  • Total revenue of $920M, including record solutions revenue of $859M; solutions revenue growth of 6.8% driven by increased volume, COVID-19 activities and new sales

NASHVILLE, Tenn.--(BUSINESS WIRE)--May 25, 2022-- Change Healthcare Inc. (Nasdaq: CHNG) (the “Company” or “Change Healthcare”), a leading healthcare technology company, today reported financial results for the fourth quarter and fiscal year ended March 31, 2022.

“The fourth quarter performance demonstrates the execution of our growth strategy, delivering on our financial objectives while continuing to make investments to advance our capabilities and support our customers and employees,” said Neil de Crescenzo, president and chief executive officer. “As we enter fiscal 2023, we remain focused on developing and delivering innovative solutions for healthcare providers, payers, partners and consumers to improve clinical, financial, and care outcomes.”

Fiscal 2022 Fourth Quarter Highlights:

Recent Business Highlights

  • Signed a strategic partnership with Luma Health that will utilize Luma's KLAS-recognized Healthcare Engagement Engine™ alongside Change Healthcare’s proven revenue cycle capabilities to develop new patient engagement solutions that seamlessly connect every touchpoint across the patient journey.
  • Integrated predictive analytics into InterQual AutoReview, enabling the solution to apply artificial intelligence to real-time EHR data and provide data-driven predictions on which level of care status is right for each patient.
  • Awarded “Best in KLAS” for Payer IT Consulting Services for the third time in four years.

Impact of McKesson Exit on Comparability of Results

On March 10, 2020, Change Healthcare Inc. acquired the interest in Change Healthcare LLC (“the Joint Venture”) previously held by McKesson. The transaction resulted in Change Healthcare Inc. acquiring control of the Joint Venture, which was accounted for as a business combination resulting in fair value adjustments to various assets and liabilities, including deferred revenue, goodwill, and intangible assets.

Financial Results for Fourth Quarter of Fiscal 2022

 

Q4 2022

Q4 2021

Total Revenue1

$920.1 million

$855.2 million

Solutions Revenue1

$859.2 million

$804.3 million

Net Income (Loss)

$7.1 million

$(13.1) million

Diluted EPS2

$0.02

$(0.04)

Adjusted EBITDA

$282.3 million

$272.0 million

Adjusted Net Income

$130.3 million

$134.0 million

Adjusted Diluted EPS2

$0.39

$0.42

1. Total Revenue and Solutions Revenue for fourth quarter of fiscal 2021 included the impact of fair value adjustments to deferred revenue resulting from the McKesson exit, which reduced revenue recognized by $10.1 million.

2. Diluted EPS and Adjusted Diluted EPS for the current period are based on 331 million shares compared to 321 million shares in the fourth quarter of fiscal 2021.

Solutions revenue in the fourth quarter grew 6.8% compared to the fourth quarter of fiscal 2021, driven by volume growth and incremental revenue from COVID-19 testing and new sales. Adjusted EBITDA grew 3.8% over the same period, reflecting the aforementioned revenue growth, partially offset by investments to support business initiatives.

Cash Flow and Balance Sheet Highlights

Net cash provided by operating activities was $696.9 million and free cash flow was $420.6 million, in each case, for the twelve months ended March 31, 2022. For the twelve months ended March 31, 2021, net cash provided by operating activities and free cash flow were $586.2 million and $339.8 million, respectively. Free cash flow increased 23.8% in the current year compared to fiscal 2021.

Net cash provided by operating activities and free cash flow each are affected by pass-thru funds we receive from certain pharmaceutical industry participants in advance of our obligation to remit these funds to participating retail pharmacies. Such pass-thru funds on hand increased by $12.9 million in the twelve months ended March 31, 2022, increasing free cash flow for the period by that amount, and decreased by $12.8 million for the twelve months ended March 31, 2021.

The Company ended the quarter with approximately $252.3 million of cash and cash equivalents, and approximately $4,590.1 million of total debt. Subsequent to the end of the quarter, the Company repaid $100.0 million of its Senior Notes.

Guidance

Due to the proposed transaction with OptumInsight, we will no longer be providing financial guidance.

Update on Proposed Merger with OptumInsight

On January 5, 2021, OptumInsight, a diversified health services company and part of UnitedHealth Group, and Change Healthcare agreed to combine (the “Merger”). Under the terms of the merger agreement, UnitedHealth Group, through a wholly-owned subsidiary, will acquire all of the outstanding shares of Change Healthcare common stock for $25.75 per share in cash. The Boards of Directors of both UnitedHealth Group and Change Healthcare have unanimously approved the terms of the Merger, and Change Healthcare stockholders voted to approve the Merger on April 13, 2021. The closing of the Merger is subject to applicable regulatory approval and other customary closing conditions.

On February 24, 2022, the Department of Justice (“DOJ”) and certain other parties commenced litigation to block the Merger, and the Company continues to support UnitedHealth Group in working toward closing the Merger. On April 4, 2022, the parties to the merger agreement entered into a waiver pursuant to which, among other things, Change Healthcare and UnitedHealth Group each waived its right to terminate the merger agreement until the earlier of (i)the tenth business day following a final order issued by the U.S. District Court for the District of Columbia with respect to the complaint filed by the DOJ that prohibits the consummation of the Merger and (ii) December 31, 2022. OptumInsight will pay a $650 million fee to Change Healthcare in the event the Merger is unable to be completed because of the decision issued by the U.S. District Court for the District of Columbia upon completion of the trial that is scheduled to begin on August 1, 2022.

Additionally, the Company will be permitted to declare and pay a one-time special dividend of up to $2.00 in cash per each issued and outstanding share of its common stock, with a record date and payment date to be determined in the sole discretion of the Company’s Board of Directors (or a committee thereof). The Company expects to pay the dividend at or about the time of closing the Merger.

On April 22, 2022, UnitedHealth Group, as seller, entered into an equity purchase agreement and related agreements relating to the sale of the Company’s claims editing business to an affiliate of investment funds of TPG Capital for a base purchase price in cash equal to $2.2 billion (subject to customary adjustments). Consummation of the transaction is contingent on a number of conditions, including the consummation of the Merger.

Webcast Information

Change Healthcare will host a conference call on Thursday, May 26, 2022, at 8:00 a.m. ET. Due to the previously announced transaction with OptumInsight, the Company will not be taking questions during the conference call.

Investors and other interested parties are invited to listen to the conference call via the Company's website at https://ir.changehealthcare.com/. The webcast will be available for on-demand listening at the aforementioned URL until May 26, 2023.

About Change Healthcare

Change Healthcare (Nasdaq: CHNG) is a leading healthcare technology company, focused on insights, innovation, and accelerating the transformation of the U.S. healthcare system through the power of the Change Healthcare platform. We provide data and analytics-driven solutions to improve clinical, financial, administrative, and patient engagement outcomes in the U.S. healthcare system. Learn more at changehealthcare.com.

CHNG-IR

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to the financial condition, results of operations and businesses of Change Healthcare. Some of these statements can be identified by terms and phrases such as “anticipate,” “believe,” “intend,” “estimate,” “expect,” “continue,” “could,” “should,” “may,” “plan,” “project,” “predict” and similar expressions. Change Healthcare cautions readers of this press release that such “forward looking statements,” including without limitation, those relating to the timing of the proposed merger and Change Healthcare’s future business prospects, revenue, working capital, liquidity, capital needs, interest costs and income, wherever they occur in this press release or in other statements attributable to Change Healthcare, are necessarily estimates reflecting the judgment of Change Healthcare’s senior management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the “forward looking statements.”

Factors that could cause Change Healthcare’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to, the inability to complete the proposed merger due to the failure to satisfy the conditions to the completion of the proposed merger, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; risks related to disruption of management’s attention from Change Healthcare’s ongoing business operations due to the transaction; the effect of the announcement of the proposed merger on Change Healthcare’s operations, results and business generally; the risk that the proposed merger will not be consummated in a timely manner, exceeding the expected costs of the merger; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; macroeconomic and industry trends and adverse developments in the debt, consumer credit and financial services markets; uncertainty and risks related to the impact of the COVID-19 pandemic (including the rise of COVID-19 variant strains such as the Delta and Omicron variants) on the national and global economy, Change Healthcare’s business, suppliers, customers, and employees; Change Healthcare’s ability to retain and recruit key management personnel and other talent (including while the proposed merger is pending); Change Healthcare’s ability to retain or renew existing customers and attract new customers; Change Healthcare’s ability to connect a large number of payers and providers; Change Healthcare’s ability to provide competitive services and prices while maintaining its margins; further consolidation in Change Healthcare’s end-customer markets; Change Healthcare’s ability to effectively manage its costs; Change Healthcare’s ability to effectively develop and maintain relationships with its channel partners; Change Healthcare’s ability to timely develop new services and improve existing solutions; Change Healthcare’s ability to deliver services timely without interruption; a decline in transaction volume in the U.S. healthcare industry; Change Healthcare’s ability to maintain access to its data sources; Change Healthcare’s ability to maintain the security and integrity of its data; Change Healthcare’s reliance on key management personnel; Change Healthcare’s ability to manage and expand its operations and keep up with rapidly changing technologies; the ability of outside service providers and key vendors to fulfill their obligations to Change Healthcare; risks related to international operations; Change Healthcare’s ability to protect and enforce its intellectual property, trade secrets and other forms of unpatented intellectual property; Change Healthcare’s ability to defend its intellectual property from infringement claims by third parties; government regulation and changes in the regulatory environment; changes in local, state, federal and international laws and regulations, including related to taxation; economic and political instability in the U.S. and international markets where Change Healthcare operates; the economic impact of escalating global tensions, including the conflict between Russia and Ukraine, and the adoption or expansion of economic sanctions or trade restrictions; litigation or regulatory proceedings; losses against which Change Healthcare does not insure; Change Healthcare’s ability to make acquisitions and integrate the operations of acquired businesses; Change Healthcare’s ability to make timely payments of principal and interest on its indebtedness; Change Healthcare’s ability to satisfy covenants in the agreements governing its indebtedness; Change Healthcare’s ability to maintain liquidity; the potential dilutive effect of future issuance of shares of Change Healthcare’s common stock; the impact of anti-takeover provisions in Change Healthcare’s organizational documents and under Delaware law, which may discourage or delay acquisition attempts; Change Healthcare’s adoption of new, or amendments to existing, accounting standards, and other risks. For a more detailed discussion of these factors, see the information under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Change Healthcare’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on May 27, 2021 as such factors may be updated from time to time in our periodic filings with the SEC.

Change Healthcare’s forward-looking statements speak only as of the date of this press release or as of the date they are made. Change Healthcare disclaims any intent or obligation to update any “forward looking statement” made in this press release to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time.

Non-GAAP Financial Measures

In the Company’s earnings releases, prepared remarks, conference calls, slide presentations and webcasts, there may be use or discussion of non-GAAP financial measures. We believe such measures provide supplemental information to investors with regards to our operating performance and assist investors’ ability to compare our financial results to those of other companies in the same industry. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between the comparable GAAP financial measure and each non-GAAP financial measure are included in this press release after the consolidated financial statements. These non-GAAP financial measures are calculated and presented on the basis of methodologies other than in accordance with GAAP. These non-GAAP financial measures should be considered only as supplemental to, and not as superior to, financial measures prepared in accordance with GAAP and may be defined and calculated differently by others in the same industry.

Consolidated Statements of Operations

(unaudited and amounts in thousands, except share and per share amounts)

 

 

 

 

 

 

 

 

 

Three Months Ended March 31,

 

 

2022

 

2021

Revenue:

 

 

 

 

 

 

Solutions revenue

 

$

859,194

 

$

804,299

Postage revenue

 

 

60,937

 

 

50,861

Total revenue

 

 

920,131

 

 

855,160

Operating expenses:

 

 

 

 

 

 

Cost of operations (exclusive of depreciation and amortization below)

 

 

362,459

 

 

357,506

Research and development

 

 

72,306

 

 

58,926

Sales, marketing, general and administrative

 

 

186,288

 

 

187,606

Customer postage

 

 

60,937

 

 

50,861

Depreciation and amortization

 

 

179,345

 

 

154,495

Accretion and changes in estimate with related parties, net

 

 

5,967

 

 

2,744

Gain on sale of businesses

 

 

 

 

1,344

Total operating expenses

 

 

867,302

 

 

813,482

Operating income (loss)

 

 

52,829

 

 

41,678

Non-operating (income) and expense

 

 

 

 

 

 

Interest expense, net

 

 

56,959

 

 

59,508

Loss on extinguishment of debt

 

 

 

 

1,289

Other, net

 

 

2,078

 

 

(2,253)

Total non-operating (income) and expense

 

 

59,037

 

 

58,544

Income (loss) before income tax provision (benefit)

 

 

(6,208)

 

 

(16,866)

Income tax provision (benefit)

 

 

(13,298)

 

 

(3,776)

Net income (loss)

 

$

7,090

 

$

(13,090)

 

 

 

 

 

 

 

Net income (loss) per common share:

 

 

 

 

 

 

Basic

 

$

0.02

 

$

(0.04)

Diluted

 

$

0.02

 

$

(0.04)

Weighted average common shares outstanding:

 

 

 

 

 

 

Basic

 

 

325,002,702

 

 

321,393,600

Diluted

 

 

330,822,467

 

 

321,393,600

Consolidated Statements of Operations

(unaudited and amounts in thousands, except share and per share amounts)

 

 

 

 

 

 

 

 

 

Year Ended March 31,

 

 

2022

 

2021

Revenue:

 

 

 

 

 

 

Solutions revenue

 

$

3,261,203

 

$

2,893,889

Postage revenue

 

 

219,612

 

 

196,532

Total revenue

 

 

3,480,815

 

 

3,090,421

Operating expenses:

 

 

 

 

 

 

Cost of operations (exclusive of depreciation and amortization below)

 

 

1,415,267

 

 

1,335,075

Research and development

 

 

277,930

 

 

227,036

Sales, marketing, general and administrative

 

 

734,554

 

 

686,645

Customer postage

 

 

219,612

 

 

196,532

Depreciation and amortization

 

 

681,808

 

 

591,048

Accretion and changes in estimate with related parties, net

 

 

14,833

 

 

13,158

Gain on sale of businesses

 

 

 

 

(59,143)

Total operating expenses

 

 

3,344,004

 

 

2,990,351

Operating income (loss)

 

 

136,811

 

 

100,070

Non-operating (income) and expense

 

 

 

 

 

 

Interest expense, net

 

 

234,244

 

 

245,241

Loss on extinguishment of debt

 

 

3,885

 

 

8,924

Other, net

 

 

4,683

 

 

(6,698)

Total non-operating (income) and expense

 

 

242,812

 

 

247,467

Income (loss) before income tax provision (benefit)

 

 

(106,001)

 

 

(147,397)

Income tax provision (benefit)

 

 

(48,611)

 

 

(35,187)

Net income (loss)

 

$

(57,390)

 

$

(112,210)

 

 

 

 

 

 

 

Net income (loss) per common share:

 

 

 

 

 

 

Basic and diluted

 

$

(0.18)

 

$

(0.35)

Weighted average common shares outstanding:

 

 

 

 

 

 

Basic and diluted

 

 

323,996,600

 

 

320,771,789

Consolidated Balance Sheets

(unaudited and amounts in thousands, except share and per share amounts)

 

 

 

 

 

 

 

 

 

March 31, 2022

 

March 31, 2021

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

252,298

 

$

113,101

Accounts receivable, net

 

 

720,122

 

 

732,614

Contract assets, net

 

 

162,828

 

 

132,856

Prepaid expenses and other current assets

 

 

177,659

 

 

140,258

Total current assets

 

 

1,312,907

 

 

1,118,829

Property and equipment, net

 

 

141,340

 

 

174,370

Operating lease right-of-use assets, net

 

 

65,680

 

 

93,412

Goodwill

 

 

4,112,904

 

 

4,108,792

Intangible assets, net

 

 

3,699,603

 

 

4,187,072

Other noncurrent assets, net

 

 

600,061

 

 

430,141

Total assets

 

$

9,932,495

 

$

10,112,616

Liabilities

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

104,273

 

$

57,449

Accrued expenses

 

 

461,506

 

 

484,293

Deferred revenue

 

 

469,098

 

 

436,666

Due to related parties, net

 

 

13,057

 

 

10,766

Current portion of long-term debt

 

 

10,006

 

 

27,339

Current portion of operating lease liabilities

 

 

21,726

 

 

30,608

Total current liabilities

 

 

1,079,666

 

 

1,047,121

Long-term debt, excluding current portion

 

 

4,580,087

 

 

4,734,775

Long-term operating lease liabilities

 

 

52,286

 

 

75,396

Deferred income tax liabilities

 

 

563,606

 

 

605,291

Tax receivable agreement obligations to related parties

 

 

104,863

 

 

103,151

Tax receivable agreement obligations

 

 

202,762

 

 

229,082

Other long-term liabilities

 

 

73,118

 

 

65,572

Total liabilities

 

 

6,656,388

 

 

6,860,388

Commitments and contingencies

 

 

 

 

 

 

Stockholders' Equity

 

 

 

 

 

 

Common Stock (par value, $0.001), 9,000,000,000 and 9,000,000,000 shares authorized and 313,131,714 and 306,796,076 shares issued and outstanding at March 31, 2022 and March 31, 2021, respectively

 

 

313

 

 

307

Preferred stock (par value, $0.001), 900,000,000 shares authorized and no shares issued and outstanding at both March 31, 2022 and March 31, 2021

 

 

 

 

Additional paid-in capital

 

 

4,340,759

 

 

4,283,391

Accumulated other comprehensive income (loss)

 

 

35,116

 

 

11,221

Accumulated deficit

 

 

(1,100,081)

 

 

(1,042,691)

Total stockholders' equity

 

 

3,276,107

 

 

3,252,228

Total liabilities and stockholders' equity

 

$

9,932,495

 

$

10,112,616

Consolidated Statements of Cash Flows

(unaudited and amounts in thousands)

 

 

 

 

 

 

 

 

 

Year Ended March 31,

 

 

2022

 

2021

Cash flows from operating activities:

 

 

 

 

 

 

Net income (loss)

 

$

(57,390)

 

$

(112,210)

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

681,808

 

 

591,048

Amortization of capitalized software developed for sale

 

 

3,509

 

 

1,326

Accretion and changes in estimate, net

 

 

25,276

 

 

11,644

Equity compensation

 

 

95,730

 

 

59,016

Deferred income tax expense (benefit)

 

 

(49,060)

 

 

(50,114)

Amortization of debt discount and issuance costs

 

 

31,284

 

 

32,532

Loss on extinguishment of debt

 

 

3,885

 

 

8,924

Non-cash lease expense

 

 

26,648

 

 

29,114

Gain on sale of businesses

 

 

 

 

(59,143)

Other, net

 

 

17,658

 

 

8,257

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable, net

 

 

12,295

 

 

(6,064)

Contract assets, net

 

 

(26,114)

 

 

158

Prepaid expenses and other assets

 

 

(82,507)

 

 

(87,540)

Accounts payable

 

 

34,825

 

 

(21,407)

Accrued expenses and other liabilities

 

 

(61,032)

 

 

14,178

Deferred revenue

 

 

40,063

 

 

166,477

Net cash provided by (used in) operating activities

 

 

696,878

 

 

586,196

Cash flows from investing activities:

 

 

 

 

 

 

Capitalized expenditures

 

 

(276,276)

 

 

(246,381)

Acquisitions, net of cash acquired

 

 

 

 

(439,483)

Proceeds from sale of businesses

 

 

 

 

115,733

Other, net

 

 

(663)

 

 

2,099

Net cash provided by (used in) investing activities

 

 

(276,939)

 

 

(568,032)

Cash flows from financing activities:

 

 

 

 

 

 

Payments on Term Loan Facility

 

 

(180,000)

 

 

(315,000)

Payments under tax receivable agreements

 

 

(21,537)

 

 

(20,691)

Receipts (payments) on derivative instruments

 

 

(22,709)

 

 

(29,538)

Employee tax withholding on vesting of equity compensation awards

 

 

(37,751)

 

 

(4,108)

Payments on deferred financing obligations

 

 

(10,991)

 

 

(19,519)

Payment of senior amortizing notes

 

 

(16,384)

 

 

(15,636)

Proceeds from exercise of equity awards

 

 

8,933

 

 

17,514

Payments on Revolving Facility

 

 

 

 

(250,000)

Proceeds from issuance of Senior Notes

 

 

 

 

325,000

Other, net

 

 

(468)

 

 

(6,800)

Net cash provided by (used in) financing activities

 

 

(280,907)

 

 

(318,778)

Effect of exchange rate changes on cash and cash equivalents

 

 

165

 

 

3,310

Net increase (decrease) in cash and cash equivalents

 

 

139,197

 

 

(297,304)

Cash and cash equivalents at beginning of period

 

 

113,101

 

 

410,405

Cash and cash equivalents at end of period

 

$

252,298

 

$

113,101

Reconciliation of Net Income (Loss) to Adjusted EBITDA

(unaudited and amounts in thousands)

 

 

 

 

 

 

 

 

Three Months Ended March 31,

 

 

2022

 

2021

Net income (loss)

 

$

7,090

 

$

(13,090)

Income tax provision (benefit)

 

 

(13,298)

 

 

(3,776)

Income (loss) before income tax provision (benefit)

 

 

(6,208)

 

 

(16,866)

Amortization of capitalized software developed for sale

 

 

999

 

 

776

Depreciation and amortization

 

 

179,345

 

 

154,495

Interest expense, net

 

 

56,959

 

 

59,508

Equity compensation

 

 

21,012

 

 

24,158

Acquisition accounting adjustments

 

 

(4,762)

 

 

5,917

Acquisition and divestiture-related costs

 

 

12,254

 

 

9,590

Integration and related costs

 

 

3,608

 

 

13,094

Strategic initiatives, duplicative and transition costs

 

 

7,977

 

 

8,671

Severance costs

 

 

(4,484)

 

 

2,717

Accretion and changes in estimate, net

 

11,706

 

 

3,215

Impairment of long-lived assets and other

 

728

 

3,772

Loss on extinguishment of debt

 

 

 

 

1,289

Gain on sale of business

 

 

 

 

1,344

Other non-routine, net

 

 

3,189

 

 

365

Adjusted EBITDA

 

$

282,323

 

$

272,045

 

Reconciliation of Net Income (Loss) to Adjusted EBITDA

(unaudited and amounts in thousands)

 

 

 

 

 

 

 

 

 

Year Ended March 31,

 

 

2022

 

2021

Net income (loss)

 

$

(57,390)

 

$

(112,210)

Income tax provision (benefit)

 

 

(48,611)

 

 

(35,187)

Income (loss) before income tax provision (benefit)

 

 

(106,001)

 

 

(147,397)

Amortization of capitalized software developed for sale

 

 

3,509

 

 

1,326

Depreciation and amortization

 

 

681,808

 

 

591,048

Interest expense, net

 

 

234,244

 

 

245,241

Equity compensation

 

 

95,730

 

 

59,016

Acquisition accounting adjustments

 

 

(11,839)

 

 

109,743

Acquisition and divestiture-related costs

 

 

41,120

 

 

19,709

Integration and related costs

 

 

26,803

 

 

40,675

Strategic initiatives, duplicative and transition costs

 

 

46,041

 

 

21,841

Severance costs

 

 

10,178

 

 

13,184

Accretion and changes in estimate, net

 

 

25,276

 

 

11,644

Impairment of long-lived assets and other

 

 

4,958

 

 

18,190

Loss on extinguishment of debt

 

 

3,885

 

 

8,924

Gain on sale of business

 

 

 

 

(59,143)

Contingent consideration

 

 

 

 

(3,000)

Other non-routine, net

 

 

15,339

 

 

3,164

Adjusted EBITDA

 

$

1,071,051

 

$

934,165

 

Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss)

(unaudited and amounts in thousands, except share and per share amounts)

 

 

 

 

 

 

 

 

 

Three Months Ended March 31,

 

 

2022

 

2021

Net income (loss)

 

$

7,090

 

$

(13,090)

Amortization expense resulting from acquisition method adjustments

 

 

125,231

 

 

117,362

EBITDA adjustments

 

 

51,228

 

 

74,132

Tax effect of EBITDA adjustments and amortization expense

 

 

(53,254)

 

 

(44,413)

Adjusted net income (loss)

 

$

130,295

 

$

133,991

 

 

 

 

 

 

 

Adjusted net income (loss) per diluted share

 

$

0.39

 

$

0.42

 

 

 

 

 

 

 

 

 

Year Ended March 31,

 

 

2022

 

2021

Net income (loss)

 

$

(57,390)

 

$

(112,210)

Amortization expense resulting from acquisition method adjustments

 

 

498,843

 

 

463,334

EBITDA adjustments

 

 

257,491

 

 

243,947

Tax effect of EBITDA adjustments and amortization expense

 

 

(204,745)

 

 

(166,324)

Adjusted net income (loss)

 

$

494,199

 

$

428,747

 

 

 

 

 

 

 

Adjusted net income (loss) per diluted share

 

$

1.53

 

$

1.34

Segment Results

(unaudited and amounts in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended March 31,

 

$

 

%

 

 

2022

 

2021

 

Change

 

Change

Segment revenue

 

 

 

 

 

 

 

 

 

 

 

Software and Analytics

 

$

443,171

 

$

416,265

 

$

26,906

 

6.5

%

Network Solutions

 

 

216,402

 

 

198,334

 

 

18,068

 

9.1

%

Technology-Enabled Services

 

 

234,262

 

 

227,311

 

 

6,951

 

3.1

%

Postage and Eliminations (1)

 

 

26,296

 

 

23,391

 

 

2,905

 

12.4

%

Purchase Accounting Adjustment (2)

 

 

 

 

(10,141)

 

 

10,141

 

(100.0

)%

Net revenue

 

$

920,131

 

$

855,160

 

$

64,971

 

7.6

%

 

 

 

 

 

 

 

 

 

 

 

 

Segment adjusted EBITDA

 

 

 

 

 

 

 

 

 

 

 

Software and Analytics

 

$

164,180

 

$

144,025

 

$

20,155

 

14.0

%

Network Solutions

 

 

103,170

 

 

108,147

 

 

(4,977)

 

(4.6

)%

Technology-Enabled Services

 

 

14,973

 

 

19,873

 

 

(4,900)

 

(24.7

)%

Postage and Eliminations

 

 

 

 

 

 

 

%

Total adjusted EBITDA

 

$

282,323

 

$

272,045

 

$

10,278

 

3.8

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended March 31,

 

$

 

%

 

 

2022

 

2021

 

Change

 

Change

Segment revenue

 

 

 

 

 

 

 

 

 

 

 

Software and Analytics

 

$

1,612,931

 

$

1,534,926

 

$

78,005

 

5.1

%

Network Solutions

 

 

868,425

 

 

717,843

 

 

150,582

 

21.0

%

Technology-Enabled Services

 

 

924,472

 

 

869,349

 

 

55,123

 

6.3

%

Postage and Eliminations (1)

 

 

82,727

 

 

96,533

 

 

(13,806)

 

(14.3

)%

Purchase Accounting Adjustment (2)

 

 

(7,740)

 

 

(128,230)

 

 

120,490

 

(94.0

)%

Net revenue

 

$

3,480,815

 

$

3,090,421

 

$

390,394

 

12.6

%

 

 

 

 

 

 

 

 

 

 

 

 

Segment adjusted EBITDA

 

 

 

 

 

 

 

 

 

 

 

Software and Analytics

 

$

561,994

 

$

526,129

 

$

35,865

 

6.8

%

Network Solutions

 

 

446,378

 

 

377,005

 

 

69,373

 

18.4

%

Technology-Enabled Services

 

 

62,679

 

 

31,031

 

 

31,648

 

102.0

%

Postage and Eliminations

 

 

 

 

 

 

 

%

Total adjusted EBITDA

 

$

1,071,051

 

$

934,165

 

$

136,886

 

14.7

%

(1)

Revenue for Postage and Eliminations includes postage revenue of $60.9 million and $50.9 million for the three months ended March 31, 2022 and 2021, respectively. Revenue for Postage and Eliminations includes postage revenue of $219.6 million and $196.5 million for the years ended March 31, 2022 and 2021, respectively.

(2)

Amount reflects the impact to deferred revenue resulting from the McKesson exit which reduced revenue recognized during the three months ended March 31, 2021 as well as the years ended March 31, 2022 and 2021.

Reconciliation of Cash Provided by (Used in) Operating Activities to Free Cash Flow and

Adjusted Free Cash Flow

(unaudited and amounts in thousands)

 

 

 

 

 

 

 

 

 

Year Ended March 31,

 

 

2022

 

2021

Cash provided by (used in) operating activities (1)

 

$

696,878

 

$

586,196

Capital expenditures

 

 

(276,276)

 

 

(246,381)

Free cash flow

 

 

420,602

 

 

339,815

Adjustments to free cash flow (2):

 

 

 

 

 

 

Integration and related costs

 

 

26,803

 

 

40,675

Strategic initiatives, duplicative and transition costs

 

 

46,041

 

 

21,841

Severance costs

 

 

10,178

 

 

13,184

Integration and strategic capital expenditures

 

 

26,166

 

 

14,379

Adjusted free cash flow

 

$

529,790

 

$

429,894

(1)

Includes cash provided by pass-thru funds of $12.9 million for the year ended March 31, 2022 and cash used by pass-thru funds of $12.8 million for Change Healthcare Inc. for the year ended March 31, 2021.

(2)

All operating costs and integration and strategic capital expenditures are presented on an as-incurred basis.

 

David Elliott
Enterprise Strategy & Investor Relations
205-907-5540
daelliott@changehealthcare.com

Katherine Wojtecki
External Communications
630-624-9142
Katherine.Wojtecki@changehealthcare.com

Source: Change Healthcare Inc.